Head-to-head evidence
UA026 vs ZL-1102
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A · full Psoriasis pipeline
UA026
Developed by Usynova Pharmaceuticals Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
ZL-1102
Developed by Zai Lab
NCT06380907 · Phase 2 · terminated
This is a randomized, quadruple-blind, placebo-controlled study using the standard validated measure of psoriasis severity as its primary endpoint, but it enrolled only 65 patients spread across five dose and placebo arms, and results have not yet been reported. The design is sound, but the small group size and the lack of posted results mean the treatment effect is not yet established.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: UA026's landscape · ZL-1102's landscape